Minimal Residual Disease Market By Product Type (Flow Cytometry, Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Others), By Technology (Hematological Malignancy and Solid Tumors), By End-user (Hospitals & Specialty Clinics, Academic & Research Institutes, Diagnostic Laboratories, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
- Published date: March 2025
- Report ID: 142600
- Number of Pages: 245
- Format:
-
-
-
- QIAGEN NV Company Profile
- Personalis
- Invitae
- Guardant Health
- GRAIL, LLC
- FOUNDATION MEDICINE, INC
- Hoffmann-La Roche Ltd
- Exact Sciences Corporation
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible